Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy

Journal of Urology

Volumn 185, Issue 2, 2011, Pages 495-500

  Stone, Nelson N ^a,b   Stone, Mariana M ^a   Rosenstein, Barry S ^a   Unger, Pam ^a   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

brachytherapy; dose response relationship, radiation; mortality; prostate; prostatic neoplasms

Indexed keywords

IODINE 125; LUTEINIZING HORMONE DERIVATIVE; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMPLANTATION; KAPLAN MEIER METHOD; LOG RANK TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BRACHYTHERAPY; COHORT STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME; TREATMENT OUTCOME;

EID: 78651276156     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.09.099     Document Type: Article

References (29)

1. A.V. Taira, G.S. Merrick, and W.M. Butler Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 2010 Epub ahead of print
2. L. Potters, Y. Cao, and E. Calugaru A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 50 2001 605
3. J.A. Cesaretti, N.N. Stone, and V.M. Skouteris Brachytherapy for the treatment of prostate cancer Cancer J 13 2007 302
4. N.N. Stone, R.G. Stock, and P. Unger Intermediate-term biochemical and local control following I-125 brachytherapy for prostate cancer J Urol 173 2005 803
5. R.G. Stock, N.N. Stone, and A. Tabert A dose-response study for I-125 prostate implants Int J Radiat Oncol Biol Phys 41 1998 101
6. L. Potters, C. Morgenstern, and E. Calugaru 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer J Urol 173 2005 1562
7. G.S. Merrick, W.M. Butler, and R.W. Galbreath Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1T3 prostate cancer Int J Radiat Oncol Biol Phys 51 2001 41
8. S. Nag, J.P. Ciezki, and R. Cormack Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society Int J Radiat Oncol Biol Phys 51 2001 1422
9. M.J. Zelefsky, Z. Fuks, and M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876
10. R.G. Stock, N.N. Stone, and J. Cesaretti Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsies Int J Rad Oncol Biol Phys 64 2006 527
11. D.G. Linzer, R.G. Stock, and N.N. Stone Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer Urology 48 1996 757
12. N.N. Stone, D.T. Marshall, and J.J. Stone Does neoadjuvant hormonal therapy improve urinary function when given to men with very large prostates undergoing prostate brachytherapy? J Urol 183 2010 546
13. A.Y. Ho, R.J. Burri, and G.T. Jennings Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined (103)Pd implantation and external beam radiation for T3c prostate cancer Brachytherapy 6 2007 38
14. R.G. Stock, N.N. Stone, and M.F. Wesson A modified technique allowing interactive ultrasound guided three-dimensional transperineal prostate implantation Int J Rad Oncol Biol Phys 32 1995 219
15. N.N. Stone, L. Potters, and B.J. Davis Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes Int J Radiat Oncol Biol Phys 69 2007 1472
16. N.N. Stone, R.G. Stock, and I. White Patterns of local failure following prostate brachytherapy J Urol 177 2007 1759
17. E.F. Miles, J.W. Nelson, and A.K. Alkaissi Equivalent uniform dose, D90, and V100 correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer Brachytherapy 7 2008 206
18. A.V. Taira, G.S. Merrick, and R.W. Galbreath Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 76 2010 349
19. B. Al-Qaisieh, T. Witteveen, and B. Carey Correlation between pre- and postimplant dosimetry for I-125 seed implants for localized prostate cancer Int J Radiat Oncol Biol Phys 75 2009 626
20. C.R. Loiselle, M. Waheed, and J. Sylvester Analysis of the Pro-Qura Database: rectal dose, implant quality, and brachytherapist's experience Brachytherapy 8 2009 34
21. M.J. Rivard, W.M. Butler, and P.M. Devlin American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions usingiodine-125 or palladium-103 Brachytherapy 6 2007 34
22. N.N. Stone, L. Potters, and B.J. Davis Effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 710 prostate cancer treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 73 2009 341
23. N.N. Stone, R.G. Stock, and J.A. Cesaretti Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes Int J Radiat Oncol Biol Phys 76 2010 335
24. R.J. Burri, N.N. Stone, and P. Unger Long-term outcomes and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 77 2010 1338
25. P. Cheetham, M. Truesdale, and S. Chaudhury Long-term cancer-specific and overall survival for men followed more than 10 years after primary and salvage cryoablation of the prostate J Endourol 24 2010 1123
26. S.A. Strope, M. Coelho, and D.P. Wood Robot-assisted salvage prostatectomy: evaluation of initial patient-reported outcomes J Endourol 24 2010 425
27. J. Kao, N.N. Stone, and A. Lavaf (125)I monotherapy using D90 implant doses of 180 Gy or greater Int J Radiat Oncol Biol Phys 70 2008 96
28. N.N. Stone, J.A. Cesaretti, and B. Rosenstein Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity? Brachytherapy 9 2010 114
29. K.M. Snyder, R.G. Stock, and S.M. Hong Defining the risk of developing grade 2 proctitis following I-125 prostate brachytherapy using a rectal dose volume histogram analysis Int J Rad Oncol Biol Phys 50 2001 335